References
- Ocheni S, Iwanski G B, Schafhausen P, Zander A R, Ayuk F, Klyuchnikov E, et al. Characterization of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk Lymphoma 2009; 50: 551–558
- Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C B, Ottmann O G, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539
- Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica 2008; 93: 1792–1796
- Kantarjian H M, O'Brien S, Cortes J E, Giralt S A, Rios M B, Shan J, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590–1595
- Breedveld P, Beijnen J H, Schellens J H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006; 27: 17–24
- Choi S J, Lee J H, Lee J H, Kim S, Seol M, Lee Y S, et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 2004; 18: 1789–1797
- Ruiz-Arguelles G J, Gomez-Almaguer D, Vela-Ojeda J, Morales-Toquero A, Gomez-Rangel J D, Garcia-Ruiz-Esparza M A, et al. Extramedullary leukemic relapses following hematopoietic stem cell transplantation with nonmyeloablative conditioning. Int J Hematol 2005; 82: 262–265
- Perez-Simon J A, Sureda A, Fernandez-Aviles F, Sampol A, Cabrera J R, Caballero D, et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 2006; 20: 542–545
- Terpos E, Rezvani K, Basu S, Milne A E, Rose P E, Scott G L, et al. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 2005; 75: 376–383